Medical cannabis-focused merchant bank Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (Frankfurt: O3X4) this morning announced the launch of Dr. Klein CBD, a new line of pharma-grade infused CBD nutraceuticals that includes skin topicals and bath products. Per the update, the initial rollout of Dr. Klein CBD will focus on the U.S. chiropractic community and online consumer marketing before rolling out globally in the fall. Redfund also welcomed Dr. Robert Klein as a U.S.-based advisor to the company. “We are pleased to support Dr. Klein and the launch of the Dr. Klein CBD brand of pharma-grade CBD topicals and infused bathing products,” Meris Kott, CEO of Redfund, stated in the news release. “These products will be laboratory tested prior to sales. We look forward to launching the Dr. Klein brand into Europe, South America and into Canada when regulation allows in the fall of 2019. Redfund will have an equity stake in the venture with further details to be released once definitive agreements are signed with Dr. Klein.”
To view the full press release, visit http://cnw.fm/ZSg0M
About Redfund Capital Corp.
Redfund intends to provide debt and equity funding in the middle to late stages of a target company’s development or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related and healthcare-related companies. For further information, visit the company’s website at www.RedfundCapital.com
NOTE TO INVESTORS: The latest news and updates relating to PNNRF are available in the company’s newsroom at http://cnw.fm/PNNRF
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CBDW? Ask our Editor
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
[email protected]
